A genetic test designed to increase the chance of IVF success

PGT-A, or preimplantation genetic testing for aneuploidies, is the process of screening IVF embryos for chromosome abnormalities prior to transfer, with the goal of increasing the likelihood of achieving a successful pregnancy. PGT-A was formerly known as PGS, preimplantation genetic screening.

PGT-A has been shown to:

  • Increase implantation rates
  • Reduce miscarriage rates
  • Increase ongoing pregnancy rates
  • Increase live birth rates
  • Reduce the time to pregnancy
  • Enable confident single embryo transfer


Our innovative PGTaiSM technology platform is clinically launched in the USA, Canada, UK and Ireland only.
Our PGT-A product is available for sale in selected countries.

Contact Us For More Information


Technology plays a central role in PGT-A

More advanced technology has been shown to produce more reliable results.

Over the years, advances in technology have played a pivotal role in the evolution of PGT. These technological innovations have driven improvements in accuracy, sensitivity and specificity of PGT-A results.

We are proud to announce the next leap in PGT-A technology. Our esteemed scientific experts have developed a revolutionary new platform in PGT-A analysis and reporting.

CooperGenomics PGT-A is performed via Next-Generation Sequencing technology and provides the best detection of:

  • Aneuploidy
  • Partial (segmental) aneuploidy
  • Unbalanced translocations
  • Some polyploidies
  • Mosaicism

Introducing PGTaiSM

CooperGenomics’ revolutionary approach to PGT-A


A new PGT-A interpretation and reporting platform

The PGTaiSM technology platform is a ground-breaking, first of its kind algorithm that harnesses the power of big data, machine learning and artificial intelligence to maximize PGT-A calling, interpretation and reporting.

  • Innovative tool that leverages the data accumulated over the history of PGT-A at CooperGenomics
  • Only analysis platform in the field built from a truth data set of known euploid pregnancies (~1000)
  • Validated using sequencing data from 10,000+ embryos, analyzed and reviewed one by one for accuracy*
  • Allows for transfer decisions based on mathematical and statistical predictions, removing the limitation of human interaction, subjectivity, and error
  • Employs machine learning to enable continuous controlled improvement
  • Improves signal clarity, increasing accuracy to ensure optimal sensitivity and specificity*

Clinically launched in the USA, Canada, UK and Ireland only.

*Internal CooperGenomics, data on file, 2018

Download our PGTaiSM

white paper

Click Here

CooperGenomics PGTaiSM Technology


Existing Technology


How PGT-A Works


Mosaicism occurs when an embryo contains both euploid and aneuploid cells as a result of errors in cell division (mitosis) made during embryo growth. With the advent of high-resolution PGT-A technology, mosaicism has emerged alongside euploidy and aneuploidy as a third category of potential PGT-A results.

Euploid embryo
Aneuploid embryo
Mosaic embryo
Number of chromosomes per cell Normal Abnormal Mixed (some normal & some abnormal)
Likelihood of producing a successful pregnancy High Very unlikely Low, but possible
Recommended for transfer Yes No No; provider may consider transfer if no euploid embryos available

Unlike traditional PGT-A technologies, CooperGenomics’ PGT-A  has been validated to reliably detect mosaic samples with 20-80% aneuploid cells. While more research is required to fully understand the clinical implications of embryonic mosaicism, current studies show that mosaic embryos implant less and miscarry more than euploid embryos, but some mosaic embryos maintain their viability and can lead to live birth. Given that, experts recommend considering mosaic embryos for transfer in cases where no euploid embryos are available and prioritizing mosaics based on the level of aneuploidy and chromosome impacted.

Our team is pioneering cutting-edge research and contributing to key scientific discussions and publications to drive a better understanding of the impact of mosaicism.

Reporting and Counseling

PGT-A reports are typically available within 14 days of sample receipt at a CooperGenomics laboratory, though we are happy to work with your team to accommodate next day results for fresh transfers, given prior notice. Reports are released to the ordering provider, with results clearly presented on the first page(s) and euploid/normal results highlighted. We are proud to be one of the first laboratories standardly reporting mosaic results, categorized as low-level mosaic, high-level mosaic, or complex abnormal.

CooperGenomics’ expert team of specially trained, board-certified genetic counselors is available for you and your patients at every point in the PGT-A testing process.

Introducing PGT Simplified

CooperGenomicsSM brings you and your patients a better PGT experience


Learn More About EngagedMD
1. Harton et al. (2013) Diminished effect of maternal age on implantation after preimplantation genetic diagnosis with array comparative genomic hybridization. Fertil Steril.
2.Fragouli et al. (2015) The developmental potential of mosaic embryos. Fertil Steril.
3.Greco et al. (2015) Healthy Babies after Intrauterine Transfer of Mosaic Aneuploid Blastocysts. N Engl J Med.